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Exposing HIV
 
On page 1407, Decker and colleagues
trick HIV into exposing itself. This
trick revealed that a majority of infected
individuals have broadly cross-reactive
neutralizing antibodies against HIV in
their circulation.
Antibodies that neutralize diverse
strains of HIV have been difficult to
find, despite decades of searching. Sev-
eral gp120-specific neutralizing anti-
bodies have been cloned. Some of them
target the binding site for the HIV co-
receptor C-C chemokine receptor 5
(CCR5), which is exposed only when
gp120 engages the CD4 receptor on
target cells. Many strains of HIV re-
quire CCR5 to infect cells, but this
binding site was thought to be weakly
antigenic as it is normally hidden from
the immune system.
Decker and colleagues now prove
this idea wrong and show that the co-
receptor binding site is one of the most
highly immunogenic regions of gp120.
The authors incubated various strains
of HIV-2 with soluble CD4 (sCD4) to
induce exposure of the coreceptor bind-
ing site. They then tested whether
plasma from HIV-1 infected individuals
could neutralize the CD4-induced virus.
To their surprise, they found that 
 
 
 
90%
of individuals infected with HIV-1 had
antibodies that could neutralize highly
divergent strains of HIV-2 and SIV, but
only when the viruses were first treated
with sCD4. This suggested that the
coreceptor binding site is not only
immunogenic, but also antigenically
conserved among different HIV strains.
The authors suggest that antibodies
against this well-concealed epitope
may be elicited in vivo by shed gp120
proteins—prevalent during HIV infec-
tion—that bind to CD4-expressing cells
causing the gp120 molecules to reveal
their coreceptor binding sites to anti-
body-producing B cells. Thus, antibodies
are generated, but are probably helpless to
attack their real target: the still hidden sites
on the gp120 of the intact virus.
Whether it will be possible to take
advantage of this antigenic site for vaccine
development remains to be seen. Pro-
viding sCD4 in vivo is unlikely to work,
as previous clinical trials showed that
sCD4 actually enhanced virus replica-
tion at low concentrations. One possi-
bility, the authors suggest, is to create a
vaccine that elicits two kinds of antibod-
ies: one that mimics CD4 and exposes
the coreceptor binding site and another
that binds the exposed site and prevents
HIV from getting into cells.
Plasma from HIV-1–infected patients neutralizes strains of HIV-2 that have been incubated 
with soluble CD4 (open circles).
 
Relief from IL-1
 
The cytokine interleukin-1 (IL-1) is primarily to blame for a severe 
type of juvenile arthritis, according to Pascual and colleagues on 
page 1479. Blocking IL-1 activity in children with systemic
onset juvenile idiopathic arthritis (SoJIA) completely resolved 
disease symptoms in a majority of children who had failed to 
respond to conventional treatments.
SoJIA is a systemic inflammatory disease of unknown 
etiology that can cause long-term arthritis in children. The 
pathogenesis of the disease is unclear, although increases 
in the inflammatory cytokine IL-6 have been reported in 
the blood of these patients. Currently the most effective 
therapy for SoJIA is long-term treatment with steroids, which 
carries with it the risk of growth retardation, osteoporosis, 
and obesity.
Pascual and colleagues now reveal a central role for IL-1—
a cytokine that plays a major role in many inflammatory and 
autoimmune diseases—in the pathology of SoJIA. They show 
that serum from SoJIA patients provokes healthy cells to 
increase expression of IL-1, but no other cytokines. In 
addition, stimulated peripheral blood cells from children with 
SoJIA produced more IL-1, but not IL-6 or TNF, compared with 
cells from healthy children.
These results prompted Pascual and colleagues to treat 
these patients with an IL-1 receptor antagonist (Anakinra). 
The results were remarkable—symptoms were completely 
resolved or significantly improved in all children with active 
arthritis, with only one later case of reversion.
The mechanism behind the increased IL-1 production in 
SoJIA is unknown. As SoJIA is not an inherited disease, the 
defect is likely to be different from familial IL-1–triggered 
inflammatory diseases in which a mutated NALP3 can no 
longer control the activation of caspase-1, which cleaves the 
IL-1
 
 
 
 precursor into the active cytokine. The authors are now 
looking for the serum component that turns on IL-1.
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Boosting innate immunity in cancer
 
Mature DCs and the NKT cell ligand 
 
 
 
-galactosyl ceramide (
 
 
 
-GalCer) are a 
promising combination for boosting immunity in humans, according to a study on 
page 1503. Chang and colleagues used 
 
 
 
-GalCer–pulsed DCs to immunize
cancer patients and showed that the treatment resulted in long-term expansion 
of both NKT cells and virus-specific CD8
 
 
 
 T cells.
 
 
 
-GalCer, a glycolipid derived from marine sponges, was identified based on 
its antitumor properties. This foreign glycolipid was later found to be presented 
to NKT cells by DCs. NKT cells activated by this glycolipid can promote tumor 
regression in mice. Attempts to extend this work to humans, however, have met 
with limited success. 
 
 
 
-GalCer treatment alone decreased NKT cell numbers in 
patients with solid tumors, and vaccination with 
 
 
 
-GalCer–pulsed immature DCs 
induced only modest and transient NKT cell expansion.
Maturation of the DCs—treatment with cytokines that enhance the 
expression of MHC and costimulatory molecules—was the key to the approach 
used by Chang and colleagues. They immunized five advanced cancer patients, 
none of whom had detectable NKT cells in their blood before treatment. But with 
 
 
 
-GalCer–pulsed mature DCs, all patients had a rapid and sustained increase in 
NKT cell numbers.
Surprisingly, CD8
 
 
 
 T cells specific for cytomegalovirus were also expanded by 
 -GalCer–pulsed DCs activate NKT cells and 
antiviral T cells in advanced cancer patients.
 
the treatment, suggesting that this approach might also be useful to boost immunity to chronic viral 
infections like HIV or hepatitis C virus, or to enhance the efficacy of T cell–based vaccines.
 
Turning fat into muscle
 
Stem cells from fat tissue have the po-
tential to become muscle, bone, or fat,
according to a study by Rodriguez
and colleagues on page 1397. These
stem cells rescued the production of
the muscle protein dystrophin in a
mouse model of Duchenne muscu-
lar dystrophy (DMD), a fatal muscle
wasting disease of children. The authors
think that these cells may eventually
be promising for treatment of children
with this deadly, and thus far untreat-
able, disease.
DMD is caused by a lack of the
cytoskeletal protein dystrophin, which
provides muscle cells with structural
stability. Several treatment strategies
for DMD are under investigation, in-
cluding gene therapy to replace the de-
fective dystrophin gene, and stem cell
transplantation to generate new dystro-
phin-producing muscle cells.
Previous work by this group and
others revealed the presence of stem cells
in human fat tissue, but their longevity in
vitro and capacity to differentiate in vivo
had not been explored. Rodriguez et al.
now show that fat tissue from young
donors yielded self-renewing stem cells
that could differentiate into muscle,
bone, or fat cells in culture, even after
100 or more cell divisions. Similar stem
cells have been found previously in bone
marrow, but fat, the authors point out,
provides a more plentiful and easily
accessible source of these cells.
Injection of the stem cells into the
muscles of dystrophin-deficient mice
restored dystrophin production and de-
creased  muscle cell necrosis, without
eliciting an immune response against the
human dystrophin protein—a protein
that is normally highly immunogenic in
mice. Why the immune system does
not respond to this foreign protein is
not known.
Another unknown is how these
stem cells become dystrophin-producing
muscle cells. One possibility—illustrated
in recent reports of stem cell therapy in
mice—is that the stem cells fuse with
local tissue cells rather than differentiating
de novo into new cells.
Stem cells from human fat differentiate into muscle cells and produce dystrophin (green) 
when injected into mice.
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